synovial sarcoma
synovial sarcoma
Explore linked clinical trials. Standard reference: MONDO:001043437 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ewing sarcoma, Eye Diseases, Hereditary, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Malignant Peripheral Nerve Sheath Tumors, Myosarcoma, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, benign urinary system neoplasm, carcinoma, clear cell sarcoma, connective tissue neoplasm, desmoplastic small round cell tumor, epithelial neoplasm, eye disorder, fibrosarcoma, hepatoblastoma, hereditary disease, hereditary neoplastic syndrome, kidney cancer, kidney disorder, mixed neoplasm, myomatous neoplasm, neoplasm, nerve sheath neoplasm, nervous system disorder, neuroblastoma, neuroepithelial neoplasm, neurofibroma, neurofibrosarcoma, neuromuscular disease, ocular cancer, osteosarcoma, peripheral nervous system disorder, peripheral nervous system neoplasm, primitive neuroectodermal tumor, retinal cancer, retinal disorder, retinoblastoma, rhabdoid tumor, rhabdomyosarcoma, sarcoma, synovial sarcoma, urinary system disorder | Active, not recruiting | Phase 1 | 2026-10-08 | NCT03618381 | |
| TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors | Disease Attributes, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Thoracic Neoplasms, adenocarcinoma, adenoma, bronchial neoplasm, bronchogenic carcinoma, carcinoma, connective tissue neoplasm, epithelial neoplasm, lung disorder, lung neoplasm, malignant mesothelioma, mesothelial neoplasm, mesothelioma, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, pleural neoplasm, primitive neuroectodermal tumor, respiratory system disorder, respiratory tract neoplasm, sarcoma, small cell lung carcinoma, synovial sarcoma | Recruiting | Phase 1 | 2026-10-01 | NCT07713732 | |
| Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ewing sarcoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Hemic and Lymphatic Diseases, Hodgkins lymphoma, Male Urogenital Diseases, Myosarcoma, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, astrocytoma (excluding glioblastoma), benign urinary system neoplasm, brain disorder, brainstem cancer, central nervous system cancer, central nervous system disorder, connective tissue neoplasm, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, ependymoma, epithelial neoplasm, glioblastoma, glioma, gliosarcoma, hereditary disease, hereditary neoplastic syndrome, immune system disorder, immunoproliferative disorder, kidney cancer, kidney disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, medulloblastoma, mixed neoplasm, myomatous neoplasm, neoplasm, nervous system disorder, neuroblastoma, neuroepithelial neoplasm, osteosarcoma, pediatric lymphoma, primitive neuroectodermal tumor, rhabdoid tumor, rhabdomyosarcoma, sarcoma, synovial sarcoma, urinary system disorder | Active, not recruiting | Phase 1 | 2026-10-01 | NCT03478462 | |
| Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, neoplasm, sarcoma, synovial sarcoma | Recruiting | Phase 3 | 2026-09-28 | NCT07174427 | |
| Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers | Neoplasms by Histologic Type, Neoplasms, Adipose Tissue, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, liposarcoma, myxoid liposarcoma, neoplasm, sarcoma, synovial sarcoma | Not yet recruiting | Phase 2 | 2026-09-25 | NCT07686367 | |
| A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Urogenital Diseases, Urogenital Neoplasms, connective tissue neoplasm, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, head and neck cancer, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, sarcoma, synovial sarcoma | Recruiting | Phase 1 | 2026-09-04 | NCT07613723 | |
| First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Adipose Tissue, Neoplasms, Connective and Soft Tissue, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, connective tissue neoplasm, liposarcoma, myxoid liposarcoma, neoplasm, sarcoma, synovial sarcoma, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Recruiting | Phase 1 | 2026-09-04 | NCT06644755 | |
| Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma | Neoplasms by Histologic Type, Neoplasms, Adipose Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, connective tissue neoplasm, dermatofibrosarcoma protuberans, fibrosarcoma, histiocytoma, leiomyosarcoma, liposarcoma, myomatous neoplasm, neoplasm, sarcoma, synovial sarcoma, undifferentiated pleomorphic sarcoma | Recruiting | Phase 1 | 2026-09-04 | NCT05711615 | |
| N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy | Neoplasms by Histologic Type, Neoplasms, Adipose Tissue, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, liposarcoma, myxoid liposarcoma, neoplasm, sarcoma, synovial sarcoma | Recruiting | Early phase 1 | 2026-08-27 | NCT07261657 | |
| Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma | Neoplasms by Histologic Type, Neoplasms, Adipose Tissue, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, liposarcoma, myxoid liposarcoma, neoplasm, sarcoma, synovial sarcoma | Active, not recruiting | Phase 2 | 2026-08-26 | NCT04044768 | |
| SPEARHEAD-3 Pediatric Study | Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, connective tissue neoplasm, epithelial neoplasm, fibrosarcoma, neoplasm, nerve sheath neoplasm, nervous system disorder, neuroblastoma, neuroepithelial neoplasm, neurofibroma, neurofibrosarcoma, neuromuscular disease, osteosarcoma, peripheral nervous system disorder, peripheral nervous system neoplasm, primitive neuroectodermal tumor, sarcoma, synovial sarcoma | Recruiting | Phase 1 / Phase 2 | 2026-08-11 | NCT05642455 | |
| Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors | Neoplasms by Histologic Type, Neoplasms, Adipose Tissue, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, liposarcoma, myxoid liposarcoma, neoplasm, sarcoma, synovial sarcoma | Active, not recruiting | Phase 2 | 2026-08-11 | NCT03967223 | |
| NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) | Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Metastatic Dermatofibrosarcoma Protuberans, Neoplasms by Histologic Type, Neoplasms, Adipose Tissue, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, Neoplasms, Nerve Tissue, Urogenital Abnormalities, Urogenital Diseases, Well Differentiated Liposarcoma, angiosarcoma, clear cell sarcoma, connective tissue neoplasm, dermatofibrosarcoma protuberans, disorder of sexual differentiation, endocrine system disorder, epithelioid hemangioendothelioma, extraskeletal myxoid chondrosarcoma, fibrosarcoma, glomus tumor, gonadal disorder, granular cell cancer, granular cell tumor, hemangioendothelioma, hemangioma, histiocytoma, Angiomatoid fibrous, inflammatory leiomyosarcoma, intimal sarcoma, leiomyosarcoma, liposarcoma, low grade fibromyxoid sarcoma, malignant myoepithelioma, malignant perineurioma, mixed neoplasm, myoepithelial tumor, myomatous neoplasm, myxofibrosarcoma, myxoid liposarcoma, neoplasm, nerve sheath neoplasm, nervous system disorder, neurofibroma, neurofibrosarcoma, neuromuscular disease, osteosarcoma, peripheral nervous system disorder, peripheral nervous system neoplasm, sarcoma, synovial sarcoma, undifferentiated (embryonal) sarcoma, vascular cancer | Recruiting | Phase 1 / Phase 2 | 2026-08-03 | NCT06239272 | |
| Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1 | Neoplasms by Histologic Type, Neoplasms, Adipose Tissue, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, liposarcoma, myxoid liposarcoma, myxoid/round cell liposarcoma, neoplasm, sarcoma, synovial sarcoma | Recruiting | Phase 1 | 2026-07-29 | NCT06083883 | |
| AOH1996 for the Treatment of Refractory Solid Tumors | Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, bronchial neoplasm, bronchogenic carcinoma, connective tissue neoplasm, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, leiomyosarcoma, lung disorder, lung neoplasm, malignant endocrine neoplasm, malignant pancreatic neoplasm, myomatous neoplasm, neoplasm, non-small cell lung carcinoma, osteosarcoma, ovarian cancer, ovarian disorder, pancreas disorder, pancreatic neoplasm, respiratory system disorder, respiratory tract neoplasm, sarcoma, synovial sarcoma | Recruiting | Phase 1 | 2026-07-28 | NCT05227326 | |
| Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, connective tissue neoplasm, endocrine system disorder, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, melanocytic neoplasm, melanoma, metastatic melanoma, neoplasm, neuroendocrine neoplasm, ovarian cancer, ovarian disorder, primitive neuroectodermal tumor, sarcoma, skin disorder, skin neoplasm, synovial sarcoma | Active, not recruiting | Phase 1 / Phase 2 | 2026-07-08 | NCT02650986 | |
| Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ewing sarcoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Myosarcoma, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Peripheral Nerve Sheath Tumors, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, alveolar soft part sarcoma, benign urinary system neoplasm, chordoma, clear cell sarcoma, connective tissue neoplasm, desmoplastic small round cell tumor, epithelial neoplasm, hereditary disease, hereditary neoplastic syndrome, kidney cancer, kidney disorder, mixed neoplasm, myoepithelial tumor, myomatous neoplasm, neoplasm, nerve sheath neoplasm, nervous system disorder, neuroblastoma, neuroepithelial neoplasm, neuromuscular disease, osteosarcoma, peripheral nervous system disorder, peripheral nervous system neoplasm, primitive neuroectodermal tumor, rhabdoid tumor, rhabdomyosarcoma, sarcoma, synovial sarcoma, urinary system disorder | Recruiting | Phase 1 / Phase 2 | 2026-06-30 | NCT06625190 | |
| XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma | Ewing sarcoma, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, bone disorder, bone sarcoma, connective tissue neoplasm, leiomyosarcoma, musculoskeletal system disorder, myomatous neoplasm, neoplasm, osteosarcoma, sarcoma, synovial sarcoma | Recruiting | Phase 2 | 2026-06-18 | NCT06571734 | |
| Synovial Sarcoma Registry / Biospecimen Repository | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, neoplasm, sarcoma, synovial sarcoma | Recruiting | Not stated | 2026-06-09 | NCT05910307 | |
| Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). | Disease Attributes, Esthesioneuroblastoma, Olfactory, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, adrenal cortex disorder, adrenal cortex neoplasm, adrenal gland cancer, adrenal gland disorder, astrocytoma (excluding glioblastoma), central nervous system cancer, connective tissue neoplasm, cranial nerve neuropathy, diffuse intrinsic pontine glioma, endocrine system disorder, ependymoma, epithelial neoplasm, glioblastoma, glioma, malignant endocrine neoplasm, medulloblastoma, meningioma, neoplasm, nervous system disorder, neuroblastoma, neuroendocrine neoplasm, neuroepithelial neoplasm, olfactory nerve disorder, osteosarcoma, paraganglioma, pheochromocytoma, primitive neuroectodermal tumor, sarcoma, synovial sarcoma, tumor of meninges, vascular cancer | Recruiting | Phase 1 / Phase 2 | 2026-06-04 | NCT06607692 | |
| MAGE-A4ᶜ¹º³²T for Multi-Tumor | Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Male Urogenital Diseases, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Adipose Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, connective tissue neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, esophageal cancer, esophageal disorder, female reproductive system disorder, female reproductive system neoplasm, gastric cancer, gastric neoplasm, gonadal disorder, head and neck cancer, liposarcoma, lung disorder, lung neoplasm, malignant endocrine neoplasm, melanocytic neoplasm, melanoma, myxoid liposarcoma, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, primitive neuroectodermal tumor, respiratory system disorder, respiratory tract neoplasm, sarcoma, skin disorder, skin neoplasm, stomach disorder, synovial sarcoma, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Active, not recruiting | Phase 1 | 2026-06-04 | NCT03132922 | |
| START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Adipose Tissue, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, colonic disorder, colorectal cancer, colorectal neoplasm, connective tissue neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, liposarcoma, lung disorder, lung neoplasm, melanocytic neoplasm, melanoma, myxoid liposarcoma, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, osteosarcoma, primitive neuroectodermal tumor, rectal disorder, respiratory system disorder, respiratory tract neoplasm, sarcoma, skin disorder, skin neoplasm, synovial sarcoma, triple-negative breast carcinoma | Recruiting | Phase 1 | 2026-05-12 | NCT05492682 | |
| Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision) | Ewing sarcoma, Myosarcoma, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, myomatous neoplasm, neoplasm, osteosarcoma, rhabdomyosarcoma, sarcoma, synovial sarcoma | Recruiting | Phase 1 / Phase 2 | 2026-05-04 | NCT06094101 | |
| B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ewing sarcoma, Eye Diseases, Hereditary, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Malignant Peripheral Nerve Sheath Tumors, Myosarcoma, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, benign urinary system neoplasm, carcinoma, clear cell sarcoma, connective tissue neoplasm, desmoplastic small round cell tumor, epithelial neoplasm, eye disorder, fibrosarcoma, hepatoblastoma, hereditary disease, hereditary neoplastic syndrome, kidney cancer, kidney disorder, melanocytic neoplasm, melanoma, mixed neoplasm, myomatous neoplasm, neoplasm, nerve sheath neoplasm, nervous system disorder, neuroblastoma, neuroendocrine neoplasm, neuroepithelial neoplasm, neurofibroma, neurofibrosarcoma, neuromuscular disease, ocular cancer, osteosarcoma, peripheral nervous system disorder, peripheral nervous system neoplasm, primitive neuroectodermal tumor, retinal cancer, retinal disorder, retinoblastoma, rhabdoid tumor, rhabdomyosarcoma, sarcoma, skin disorder, skin neoplasm, synovial sarcoma, urinary system disorder | Active, not recruiting | Phase 1 | 2026-04-28 | NCT04483778 | |
| Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, Neoplasms, Nerve Tissue, connective tissue neoplasm, dermatofibrosarcoma protuberans, fibrosarcoma, histiocytoma, leiomyosarcoma, malignant giant cell tumor of soft parts, myomatous neoplasm, myxofibrosarcoma, neoplasm, nerve sheath neoplasm, nervous system disorder, neurofibroma, neurofibrosarcoma, neuromuscular disease, peripheral nervous system disorder, peripheral nervous system neoplasm, pleomorphic rhabdomyosarcoma, sarcoma, synovial sarcoma, undifferentiated high grade pleomorphic sarcoma of bone, undifferentiated pleomorphic sarcoma, undifferentiated pleomorphic sarcoma, inflammatory variant | Active, not recruiting | Phase 1 | 2026-03-10 | NCT04420975 |